Shionogi looks to new products, in-house R&D to weather Crestor expiries
This article was originally published in Scrip
Executive Summary
Shionogi is aiming to raise its consolidated net sales to ¥375 billion ($4.1 billion) over the next five years, ahead of a challenging period after 2016 when cholesterol therapy Crestor (rosuvastatin) will be hit by its first patent expiries.